/**/ document.writeln("\n\n\n\n\n \n\n\n\n\n \n \n \n\n
\n\n \n
\n \n \n \n \n
 Recent News for Amarillo Biosciences Inc.\n \n\n\n\n\n
Nov 21 2:36 AM EST
\n\n\n\n
\n \n
\n \n \n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n
\n\n Nov 11, 2009 8:00 AM EST
\n\n \n Amarillo Biosciences Comments on New Findings of H1N1 in Animals and Potential Effect on Human Infections - Marketwire\n \n \n
\n\n Oct 09, 2009 11:45 AM EDT
\n\n \n Amarillo Biosciences Reports on Research Supporting Use of Interferon to Combat Influenza - Marketwire\n \n \n
\n\n Oct 07, 2009 10:28 AM EDT
\n\n \n Amarillo Biosciences Partners With Intas Pharmaceuticals to Treat Influenza in India - Marketwire\n \n \n
\n\n Sep 29, 2009 8:02 AM EDT
\n\n \n Amarillo Biosciences Appoints Bernard Cohen CFO - PR Newswire\n \n \n
\n\n Sep 08, 2009 1:05 PM EDT
\n\n \n Amarillo Biosciences' Phase 2 Australian Clinical Study of Interferon as a Preventative Agent Against H1N1 Flu Virus and Other Cold and Flu Viruses Reaches Midway Point - Marketwire\n \n \n
\n\n Aug 17, 2009 10:33 AM EDT
\n\n \n Dr. Manfred Beilharz, Co-Investigator in Australian Influenza Phase 2 Clinical Trial, Interviewed on 6PR Nightline Program Regarding Interferon and Influenza - Marketwire\n \n \n
\n\n Jul 10, 2009 11:34 AM EDT
\n\n \n Amarillo Biosciences Reaches Enrollment Goal in Australian Influenza Phase 2 Clinical Trial - Marketwire\n \n \n
\n
\n\n");